Get started
Author

Sandra Di Gregorio

Observed names: S. Di Gregorio, SANDRA DI GREGORIO, Sandra Di Gregorio
Observed institutions: Magna Graecia University, University of Catania, Policlinico Universitario di Catania, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco", University of Turin, University of Milano-Bicocca
ORCID: 0000-0002-6015-746X
Observed ORCID: 0000-0002-6015-746X
OpenAlex ID: A5014708779
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
2019 · Elena Tirrò, Federica Martorana, et al. · Genes · 101
Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment
2019 · Livia Manzella, Michele Massimino, et al. · International Journal of Molecular Sciences · 58
PDF
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B
2005 · Alessandra Aloisi, Sandra Di Gregorio, et al. · Blood · 57
PDF
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma
2021 · Elena Tirrò, Michele Massimino, et al. · Frontiers in Oncology · 44
PDF
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives
2020 · MICHELE MASSIMINO, STEFANIA STELLA, et al. · Anticancer Research · 37
PDF
Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer
2021 · Chiara Romano, Federica Martorana, et al. · International Journal of Molecular Sciences · 30
PDF
Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes
2021 · Stefania Stella, Michele Massimino, et al. · International Journal of Molecular Sciences · 22
PDF
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
2021 · Michele Massimino, Elena Tirrò, et al. · Frontiers in Pharmacology · 17
PDF
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
2019 · Maria Stella Pennisi, Stefania Stella, et al. · Frontiers in Oncology · 17
PDF
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22)
2019 · ELENA TIRRÒ, MICHELE MASSIMINO, et al. · Anticancer Research · 14
PDF
Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells
2020 · MICHELE MASSIMINO, ELENA TIRRÒ, et al. · In Vivo · 13
Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report
2019 · Elena Tirrò, Stefania Stella, et al. · Acta Haematologica · 11
Detection and Clinical Implications of a Novel BCR-ABL1 E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform
2019 · STEFANIA STELLA, MICHELE MASSIMINO, et al. · Anticancer Research · 10
PDF
Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib
2019 · STEFANIA STELLA, ELENA TIRRÓ, et al. · In Vivo · 9
PDF
Optimal Response in a Patient With CML Expressing BCR–ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report
2020 · LIVIA MANZELLA, ELENA TIRRÒ, et al. · In Vivo · 7
PDF
Multiple primary malignances managed with surgical excision: a case report with next generation sequencing analysis
2022 · Chiara Romano, Sandra Di Gregorio, et al. · Molecular Biology Reports · 4
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports
2023 · Maria Stella Pennisi, Sandra Di Gregorio, et al. · Hematology Reports · 2
PDF
Anatomical distribution of Cancer Stem Cells between Enhancing Nodule and FLAIR hyperintensity in supratentorial Glioblastoma: time to recalibrate the surgical target?
2022 · R. Altieri, F. Certo, et al. · Brain and Spine
PDF
Works count: 18
Citation count: 453
H-index: 11
I10-index: 13
Year
Topic
Type